Abeona Therapeutics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Joseph Walter Vazzano, Chief Financial Officer of Abeona Therapeutics Inc., sold 1,478 shares of common stock on July 21, 2026 for $6.53 per share.
NASDAQ
Abeona Therapeutics Chief Financial Officer, Joseph Vazzano, reported a sale of 24,880 shares of common stock on July 9, 2026, to cover tax obligations.
NASDAQ
Abeona Therapeutics CEO Vishwas Seshadri reported a sale of 67,971 shares of common stock on July 9, 2026, to cover tax obligations from vested stock awards.
NASDAQ
Abeona Therapeutics SVP, Chief Legal Officer Brendan O'Malley reported a sale of 12,050 shares of common stock on July 9, 2026, to cover tax obligations.
NASDAQ
Abeona Therapeutics Chief Commercial Officer, Vasanthavada Madhav, reported a transaction involving the sale of common stock.
NASDAQ
Director Christine Silverstein sold 18,160 shares of Abeona Therapeutics to satisfy tax obligations related to restricted stock vesting.
NASDAQ
Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics, sold 11,131 shares to cover tax withholding requirements.
NASDAQ
CFO Joseph Vazzano sold 49,338 shares of Abeona Therapeutics to cover tax obligations related to restricted stock vesting.
NASDAQ
Chief Commercial Officer Madhav Vasanthavada sold 9,620 shares of Abeona Therapeutics to cover tax obligations.
NASDAQ
Abeona Therapeutics CEO Vishwas Seshadri sold 56,344 shares to cover tax liabilities related to restricted stock vesting.
NASDAQ
Abeona Therapeutics Director Mark Alvino reported the acquisition of 500 common shares.
NASDAQ
Abeona Therapeutics director Mark Alvino sold 6,500 shares of common stock at a weighted average price of $5.4558.
NASDAQ
Abeona Therapeutics Director Eric Crombez sold 26,143 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Chief Commercial Officer Madhav Vasanthavada sold 5,548 shares of Abeona Therapeutics to cover tax obligations related to restricted stock vesting.
NASDAQ
Director Keith A. Goldan was granted 32,751 shares of restricted stock in Abeona Therapeutics, scheduled to vest in April 2027.
NASDAQ
ABEONA THERAPEUTICS CEO Vishwas Seshadri sold 29,985 shares of common stock for a weighted average price of $4.3849 per share under a pre-arranged 10b5-1 trading plan.
NASDAQ
Abeona Therapeutics CFO Joseph Vazzano sold 785 shares of common stock at $4.76 per share to cover tax obligations related to restricted stock vesting.
NASDAQ
Abeona Therapeutics Director Christine Silverstein sold 20,070 shares of common stock to cover tax obligations related to restricted stock awards.
NASDAQ
Abeona Therapeutics Director Donald A. Wuchterl sold 14,814 shares of common stock to cover tax obligations associated with restricted stock vesting.
NASDAQ
Abeona Therapeutics director Eric Crombez sold 16,284 shares of common stock to cover tax obligations related to restricted stock awards.
NASDAQ
Abeona Therapeutics director Mark Alvino sold 2,000 shares of common stock to cover tax obligations related to restricted stock awards.
NASDAQ
Donald A. Wuchterl, a director at Abeona Therapeutics Inc., acquired 37,313 shares of common stock as restricted stock, vesting on January 26, 2027.
NASDAQ
ABEONA THERAPEUTICS Director Bernhardt G Zeiher acquired 37,313 shares of common stock on January 26, 2026, increasing his direct beneficial ownership to 84,458 shares.
NASDAQ
Abeona Therapeutics Director Eric Crombez acquired 37,313 shares of common stock as a restricted stock grant, vesting on January 26, 2027.
NASDAQ
ABEONA THERAPEUTICS INC. Director Christine Berni Silverstein acquired 37,313 shares of common stock as restricted stock, vesting on January 26, 2027.
NASDAQ
ABEONA THERAPEUTICS Director Michael Amoroso acquired 37,313 shares of common stock, increasing his beneficial ownership to 217,779 shares.
NASDAQ
ABEONA THERAPEUTICS Director Faith L. Charles acquired 37,313 shares of common stock, increasing her beneficial ownership to 176,407 shares.
NASDAQ
ABEONA THERAPEUTICS Director Mark Alvino acquired 37,313 shares of common stock, increasing his beneficial ownership to 86,065 shares, with vesting set for January 26, 2027.
NASDAQ
Abeona Therapeutics Director Leila Alland received a grant of 37,313 shares of common stock, increasing her beneficial ownership.
NASDAQ
Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, reported the acquisition of restricted stock and a subsequent sale to cover tax obligations.